NASDAQ · Medical - Diagnostics & Research

MYGN (MYGN) Stock

$2.86 -46.74% NASDAQ: MYGN Healthcare

Valuation

MetricValue
Price$2.86
Market Cap$270.12M
P/E Ratio-0.91
P/B Ratio0.93
P/S Ratio0.42
EPS (TTM)$-3.96
52-Week High$8.59
52-Week Low$2.86
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-99.46%
ROA-51.77%
ROCE-18.48%
Gross Margin-8.12%
Operating Margin-8.24%
Net Margin-48.24%
Debt/Equity0.63
Current Ratio2.49

Annual Financials (USD)

Metric20212022202320242025
Revenue$691.0M$678.0M$753.0M$838.0M$825.0M
Operating Profit$-190.0M$-141.0M$-257.0M$-123.0M$-68.0M
Net Profit$-27.0M$-112.0M$-263.0M$-127.0M$-366.0M
EPS$-0.35$-1.39$-3.18$-1.41$-3.96
Op Margin-27.6%-20.7%-34.2%-14.7%-8.2%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.3B$1.2B$1.1B$1.0B$707.0M
Total Liabilities$353.0M$313.0M$363.0M$327.0M$339.0M
Cash$258.0M$57.0M$132.0M$102.0M$150.0M
Borrowings$92.0M$145.0M$152.0M$140.0M$210.0M

Latest News

Is This the Right Time to Hold MYGN Stock in Your Portfolio? Zacks · Jul 15, 2026 New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer GlobeNewswire · Jul 2, 2026 1 Unpopular Stock That Should Get More Attention and 2 We Find Risky StockStory · Jul 1, 2026 Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1 StockStory · Jun 30, 2026 Myriad (MYGN) Soars 8.3%: Is Further Upside Left in the Stock? Zacks · Jun 29, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$19.0M$-106.0M$-111.0M$-9.0M$2.0M
Investing Cash Flow$256.0M$-123.0M$-41.0M$-42.0M$-43.0M
Financing Cash Flow$76.0M$-8.0M$-4.0M$-7.0M$-15.0M
Net Cash Flow$142.0M$-192.0M$75.0M$-29.0M$39.0M
Free Cash Flow$1.0M$-152.0M$-184.0M$-38.0M$-14.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-5.98%
Quick Ratio2.19
Interest Coverage-6.18
Return 1Y20.25%
Return 3Y-74.11%
Return 5Y-80.68%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AMN $31.17 -4.97% -11.68 $1.21B 0.00%
CDNA $43.71 +14.72% 18.87 $2.26B 0.00%
CSTL $24.44 -0.99% -23.63 $741.26M 0.00%
DNA $8.07 -0.19% -1.30 $527.50M 0.00%
DRIO $7.47 -4.11% -10.51 $54.62M 0.00%

About MYGN

MYGN is led by CEO Samraat S. Raha, employs 2,700 people, headquartered in US, publicly traded since 1995.

MYGN stock trades at $2.86 with a market capitalization of $270.12M. The stock is valued at a price-to-earnings (P/E) ratio of -0.91, price-to-book of 0.93, price-to-sales of 0.42. Over the past 52 weeks the stock has ranged between $2.86 and $8.59, and currently trades 66.7% below its 52-week high.

On profitability, MYGN generates a return on equity (ROE) of -99.46%, return on capital employed of -18.48%, an operating margin of -8.24%, a net profit margin of -48.24%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides